Amir Hesam Karbakhsh: The Science Behind Platelet-Rich Plasma Preparation
Amir Hesam Karbakhsh, Medical Equipment and Sales Specialist at Salamat Tajhiz Barsava, shared a post on LinkedIn:
“The therapeutic layer in PRP isn’t the layer most people picture.
Spin a tube of whole blood and it separates into three distinct bands, not two — density is doing all the work here.
1. Platelet-Poor Plasma (top, approximately 1.025 g/mL)
Mostly water and proteins.
Often discarded or used separately — this is NOT the therapeutic layer, even though it’s the biggest and most visible one.
2. Buffy Coat (thin middle band, approximately 1.06 g/mL)
This is the actual PRP — a concentrated band of platelets and white blood cells.
Many clinical protocols re-spin this layer specifically (a ‘double-spin’ protocol) to concentrate platelets further before injection.
3. Red Blood Cells (bottom, approximately 1.09–1.11 g/mL)
Heaviest layer.
Centrifugal force scales with radius and the square of angular velocity, so denser particles get pushed outward — and settle at the bottom — fastest.
Where it actually goes wrong in practice isn’t the physics, it’s the execution:
- Unbalanced tubes vibrate the rotor and can damage the bearings
- Over-speeding shears platelets and causes hemolysis, contaminating the very layer you’re trying to concentrate
- Drawing off the buffy coat too high or too low dilutes the final platelet concentration
Same lesson as the last few posts: in biomedical devices, the ‘boring’ physical process — not the marketing term on the box — determines whether the output is actually clinically useful.”

Stay updated with Hemostasis Today.
-
Oct 18, 2026, 13:0810 Posts Not to Miss This Week
-
Oct 18, 2026, 12:58Pierpaolo Di Micco: DOACs vs Vitamin K Antagonists in Long-Term Anticoagulation
-
Oct 18, 2026, 12:51Arianne Missimer: Understanding Ferritin Levels Beyond the Normal Range
-
Oct 18, 2026, 12:37Roberto C. Iglesias: Colon Cancer Prevention Beyond Supplements and Vitamins
-
Oct 18, 2026, 12:27Rafael Alejandro Camero Del Vecchio: Paroxysmal Nocturnal Hemoglobinuria Advancing Complement Inhibition with Ravulizumab
-
Oct 18, 2026, 12:26Abdul Mannan: When INR Misleads – Rethinking Bleeding Risk in Cirrhosis
-
Oct 18, 2026, 12:14Stéphane Laurent: The People and Technology Behind Safe Blood Transfusion
-
Oct 18, 2026, 12:14Abhi Kapuria: When VTE Prophylaxis Breaks Down in the ICU
-
Oct 18, 2026, 11:37Lee Anne Sorto: Beyond Compliance – Making Audits Count in Transfusion Safety